MILESTONE PHARMACEUTICALS IN (MIST) Stock Price, Quote, News and Overview
NASDAQ:MIST - Nasdaq - CA59935V1076 - Common Stock - Currency: USD
MIST Quote, Performance and Key Statistics
2.04
-0.02 (-0.97%)
The current stock price of MIST is 2.04 USD. In the past month the price decreased by -0.49%. In the past year, price increased by 20%.
MIST Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About MIST
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 47 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Company Info
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 47
Company Website: https://www.milestonepharma.com
Investor Relations: http://investors.milestonepharma.com
Phone: 15143360444
MILESTONE PHARMACEUTICALS IN / MIST FAQ
What is the stock price of MILESTONE PHARMACEUTICALS IN today?
The current stock price of MIST is 2.04 USD. The price decreased by -0.97% in the last trading session.
What is the ticker symbol for MILESTONE PHARMACEUTICALS IN stock?
The exchange symbol of MILESTONE PHARMACEUTICALS IN is MIST and it is listed on the Nasdaq exchange.
On which exchange is MIST stock listed?
MIST stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MILESTONE PHARMACEUTICALS IN stock?
10 analysts have analysed MIST and the average price target is 10.88 USD. This implies a price increase of 433.33% is expected in the next year compared to the current price of 2.04. Check the MILESTONE PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MILESTONE PHARMACEUTICALS IN worth?
MILESTONE PHARMACEUTICALS IN (MIST) has a market capitalization of 108.79M USD. This makes MIST a Micro Cap stock.
How many employees does MILESTONE PHARMACEUTICALS IN have?
MILESTONE PHARMACEUTICALS IN (MIST) currently has 47 employees.
What are the support and resistance levels for MILESTONE PHARMACEUTICALS IN (MIST) stock?
MILESTONE PHARMACEUTICALS IN (MIST) has a support level at 2 and a resistance level at 2.28. Check the full technical report for a detailed analysis of MIST support and resistance levels.
Is MILESTONE PHARMACEUTICALS IN (MIST) expected to grow?
The Revenue of MILESTONE PHARMACEUTICALS IN (MIST) is expected to decline by -100% in the next year. Check the estimates tab for more information on the MIST EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MILESTONE PHARMACEUTICALS IN (MIST) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MIST, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MIST, evaluating the profitability, health, valuation and growth aspects
- MILESTONE PHARMACEUTICALS IN (MIST) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MILESTONE PHARMACEUTICALS IN (MIST) Sales and EPS estimates to see what analysts future expectations are.
- MILESTONE PHARMACEUTICALS IN (MIST) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MILESTONE PHARMACEUTICALS IN (MIST) Insider and Institutional Ownership to learn about the owners and their transactions.
- MILESTONE PHARMACEUTICALS IN (MIST) Stock Chart to make your own analysis
- MILESTONE PHARMACEUTICALS IN (MIST) Latest news and press-releases to stay up to date.
Does MILESTONE PHARMACEUTICALS IN (MIST) stock pay dividends?
MIST does not pay a dividend.
When does MILESTONE PHARMACEUTICALS IN (MIST) report earnings?
MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2025-03-19, after the market close.
What is the Price/Earnings (PE) ratio of MILESTONE PHARMACEUTICALS IN (MIST)?
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.81).
What is the Short Interest ratio of MILESTONE PHARMACEUTICALS IN (MIST) stock?
The outstanding short interest for MILESTONE PHARMACEUTICALS IN (MIST) is 0.94% of its float. Check the ownership tab for more information on the MIST short interest.
MIST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MIST. When comparing the yearly performance of all stocks, MIST is one of the better performing stocks in the market, outperforming 82.91% of all stocks.
MIST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MIST. The financial health of MIST is average, but there are quite some concerns on its profitability.
MIST Financial Highlights
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 41.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.71% | ||
| ROE | -178.11% | ||
| Debt/Equity | 2.18 |
MIST Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to MIST. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 54.32% and a revenue growth -100% for MIST